71 results on '"D. Robesti"'
Search Results
2. Exploring the effect of metastasis directed therapy on progression patterns of patients with positive 68Ga-PSMA PET/CT and biochemical recurrence from prostate cancer
3. Does prostate cancer family history have an impact on active surveillance adherence in men with low- or favourable intermediate risk disease?
4. The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer patients receiving atezolizumab: Analysis of individual participant data from IMvigor210 and IMvigor211
5. Is there an impact of the center performing baseline multiparametric MRI on active surveillance outcomes in prostate cancer patients?
6. Identifying the optimal candidates for concomitant androgen-deprivation therapy among patients receiving metastasis-directed therapy for positive 68Ga-PSMA PET/CT for biochemical recurrent prostate cancer after radical prostatectomy
7. Impact of radiologist expertise on PI-RADS distribution and detection of clinically significant prostate cancer: Results from a single, high volume center
8. When is central histological review of prostate biopsy really needed to reduce the risk of misclassification of prostate cancer? The importance of patient risk stratification
9. Is there a preferential lymph node metastasis pathway in prostate cancer according to the site of the index lesion at multiparametric MRI? A topographic mapping study
10. Assessing the impact of TURBT specimens review by a dedicated uropathologist on clinical decision making process: Results from a single tertiary referral center
11. A patient tailored follow-up protocol for men with prostate cancer managed with active surveillance with the use of multiparametric magnetic resonance imaging: Identifying predictors of early and late reclassification in a large single institution cohort
12. Development and validation of a novel nomogram predicting long-term progression in patients treated with early salvage radiation therapy after radical prostatectomy: the key role of PSA kinetics
13. Reliability of 68Ga-PSMA PET/CT in assessing real nodal burden in men with cN1 disease: clinical implications for patient counselling and multi-modal treatments
14. Histological variants of prostate cancer are under-reported in prostate biopsies assessed outside tertiary referral centers. a plea for biopsy review for optimal patient management
15. Assessing the role of frailty status on oncologic and functional outcomes in patients treated with robot-assisted radical prostatectomy for localized prostate cancer
16. The risk of recurrence in cN1 prostate cancer patients treated with radical prostatectomy varies according to the type preoperative staging. a comparison between 68ga-PSMA-PET versus conventional imaging in a large, multi-institutional study
17. Optimizing timing and indications for 68Ga-PSMA PET/CT in patients with biochemical recurrent prostate cancer after radical prostatectomy
18. Impact of Prostate Imaging Quality (PI-QUAL) score on the detection of clinically significant prostate cancer in men undergoing MRI-targeted biopsy
19. The prognostic role of 68Ga-PSMA PET/CT and the impact of metastasis-directed therapy on cancer progression in men with biochemical recurrence from prostate cancer. Results from a large, single Institution series
20. Defining the optimal target-to-background count rate to identify positive lymph nodes in patients undergoing robot-assisted 99mtc-PSMA-radioguided surgery for prostate cancer: A per-region analysis of a prospective, phase II study
21. Tailoring the optimal use of androgen-deprivation therapy concomitant to post-operative radiotherapy among men with pN1 prostate cancer. Long-term results of a large, single Institution series
22. Delaying post-operative radiation therapy after radical prostatectomy is associated with increased functional outcomes: results from a large single, referral center series
23. The impact of frailty status on surgical outcomes after robot-assisted radical prostatectomy - a prospective assessment using a standardized collection system for perioperative outcomes
24. Are extended pelvic lymph node dissection-related complications still an issue in contemporary patients treated with robot-assisted radical prostatectomy? a prospective assessment using a standardized collection system
25. Increased awareness of surgical outcomes improves long-term functional outcomes after robot-assisted radical prostatectomy. A prospective assessment following implementation of prospective data collection
26. A timely administration of metastasis-directed therapy can reduce the risk of disease progression in men with positive 68Ga-PSMA PET/CT for biochemical recurrence after radical prostatectomy
27. When node-positive prostate cancer should be considered a systemic disease? assessing the prognostic role of preoperative 68Ga-PSMA PET/ CT results in patients with lymph node invasion at final pathology
28. Detection of clinically significant prostate cancer in mpMRI visible lesions: size matters. Results from a large, two-institutional series
29. Oncological outcomes, patterns of recurrence and impact of competing causes of mortality in clinically node-positive prostate cancer patients treated with radical prostatectomy
30. Impact of 68Ga-PSMA PET/CT and metastasis-directed therapy on clinical recurrence in patients with biochemical recurrence after radical prostatectomy. results from a single center series
31. 99M-technetium-psma radio-guided surgery to detect nodal metastases in prostate cancer patients undergoing radical prostatectomy and extended pelvic lymph node dissection: a phase 2 prospective, single-institution study
32. The impact of histological variants on the performance characteristics of 68Ga-PSMA PET/CT in the primary and recurrent setting
33. Optimizing timing and indications for 68Ga-PSMA PET/CT in patients with biochemical recurrent prostate cancer after radical prostatectomy
34. Detection of clinically significant prostate cancer in mpMRI visible lesions: Size matters. Results from a large, two-institutional series
35. The risk of recurrence in cN1 prostate cancer patients treated with radical prostatectomy varies according to preoperative staging. A comparison between 68Ga-PSMA-PET versus conventional imaging in a large, multi-institutional study
36. Does a positive multi-parametric MRI always warrant prostate biopsy? The importance of integrating clinical and imaging data based on a large, multi-institutional series
37. A timely administration of metastasis-directed therapy can reduce the risk of disease progression in men with positive 68Ga-PSMA PET/CT for biochemical recurrence after radical prostatectomy
38. Development and validation of a novel nomogram predicting long-term progression in patients treated with early salvage radiation therapy after radical prostatectomy: The key role of PSA kinetics
39. Delaying post-operative radiation therapy after radical prostatectomy is associated with increased functional outcomes: Results from a large single, referral center series
40. Can pelvic lymph node dissection be omitted at the time of radical prostatectomy in patients with a negative preoperative 68Ga-PSMA PET/CT? The importance of patient risk stratification according to individual risk of lymph node metastases
41. Assessing the role of frailty status on surgical, oncologic and functional outcomes in patients treated with robot-assisted radical prostatectomy for prostate cancer
42. When is neoadjuvant androgen deprivation therapy beneficial for highly aggressive prostate cancer before radical prostatectomy? Implications for multi-modal tailored approaches and trials design
43. Does centralized revision of prostate biopsy impact on active surveillance outcomes? Results from a single, high-volume institution series
44. Development and external validation of a novel tool predicting lymph node invasion in patients with prostate cancer detected at targeted-biopsies
45. Saturation of the MPMRI lesion is not necessary to minimize the risk of missing clinically significant prostate cancer at targeted biopsy. Analysis of a large, multi-institutional series
46. Which patients with Oligometastatic Prostate Cancer should be considered for Cytoreductive Radical Prostatectomy as part of a multimodal treatment? Results from a large, multi-institutional collaboration
47. Oncological outcomes, patterns of recurrence and impact of competing causes of mortality in clinically node-positive prostate cancer patients treated with radical prostatectomy
48. The key role of concomitant androgen-deprivation therapy on the efficacy of imaging guided treatments in men with biochemical recurrent prostate cancer after radical prostatectomy and 68Ga-PSMA PET/CT scan
49. Increased awareness of surgical outcomes improves long-term functional outcomes after robot-assisted radical prostatectomy. A prospective assessment following implementation of prospective data collection
50. Are extended pelvic lymph node dissection-related complications still an issue in contemporary patients treated with robot-assisted radical prostatectomy? A prospective assessment using a standardized collection system
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.